

DAFTAR PUSTAKA

- Albazzaz, F., Alkotaji, M., 2018. *Ophthalmic In-Situ Sustained Gel of Ciprofloxacin, Preparation and Evaluation Study*. Int. J. Appl. Pharm. 10, 153–161.
- Ashish Namdeo¹, Santosh Bhadkariya², Akanksha Garud^{*2}, N.G., 2016. *Formulation and Evaluation of an Ophthalmic In-Situ Gel Of Gentamicin Sulphate*. World J. Pharm. Res. Garud 5, 974–982.
- Bairagi, S.H., 2018. *Acanthamoeba Keratitis: Diagnosis and Treatment*. J. Rare Disord. Diagnosis Ther. 03, 3–4.
- Desai, M. and Kapadia, J. 2018. 'Factors Affecting Intra-ocular Bioavailability of Drugs', (October 2017), pp. 1–32.
- Domínguez delgado, C. L. et al. 2016. 'Chitosan and Pluronic ® F-127: Pharmaceutical Applications Encyclopedia of Biomedical Polymers and Polymeric Chitosan and Pluronic F-127: Pharmaceutical Applications', (June). doi: 10.1081/E-EBPP-120050057.
- Dubald, M. et al. 2018. 'Ophthalmic drug delivery systems for antibiotherapy- A review', *Pharmaceutics*, 10(1). doi: 10.3390/pharmaceutics10010010.
- Gadad, A.P., Wadklar, P.D., Dandghi, P., Patil, A., 2016. *Thermosensitive In situ Gel for Ocular Delivery of Lomefloxacin*. Indian J. Pharm. Educ. Res. 50, 96–105.
- Gupta, C., Juyal, V., Nagaich, U., 2018. *Formulation and optimization of thermosensitive in-situ gel of moxifloxacin hydrochloride for ocular drug delivery*. Int. J. Appl. Pharm. 10, 123–130.
- Güven, U.M., Berkman, M.S., Şenel, B., Yazan, Y., 2010. *in Situ Gelling Systems for Ocular Allergy*.
- Hernández Ceruelos, A. et al. 2019. 'Therapeutic uses of metronidazole and its side effects: An update', *European Review for Medical and Pharmacological Sciences*, 23(1), pp. 397–401. doi: 10.26355/eurrev_201901_16788.
- Jacob, L., A, K.N., Julia, W., 2015. *An update on Acanthamoeba keratitis: Diagnosis, pathogenesis and treatment*. Parasite 22, 1–19.
- Jain, D., Kumar, V., Singh, S., Mullertz, A., Bar-Shalom, D., 2016. *Newer Trends in In Situ Gelling Systems for Controlled Ocular Drug Delivery*. J. Anal. Pharm. Res. 2, 1–16.
- Jones, D. 2008. *FASTtrack: Pharmaceutics – Dosage Form and Design*. London: Pharmaceutical Press.

- Kamel, M., Ghani, A., Lumpur, K., Faridah, H., Yogyakarta, U.N., Ahmad, N., 2005. *A case of trauma related Acanthamoeba keratitis*. Trop. Biomed. 1–6.
- Kementerian Kesehatan, R., 2014. *Farmakope Indonesia Edisi V Jilid 1*, Jakarta.
- Khateb, Kosai, A., Ozhmukhametova, Elvira, K., Mussin, Marat, N., Seilkhanov, Serzhan, K., Rakhypbekov, Tolebai, K., Lau, Wing, M., Khutoryanskiy, Vitaliy, V., 2016. *In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery*. Int. J. Pharm. 502, 70–79.
- Khattab, A., Marzok, S., Ibrahim, M., 2019. *Development of optimized mucoadhesive thermosensitive pluronic based in situ gel for controlled delivery of Latanoprost : Antiglaucoma efficacy and stability approaches*. J. Drug Deliv. Sci. Technol. 53, 101134.
- Kodym, A., Dyba-Kaczynska, E., Kubiak, B., Kukula, H., 2011. *Technology of eye drops containing metronidazole*. Acta Pol. Pharm. 68, 109–114.
- Lieberman, Rieger & Banker, 1989, *Pharmaceutical Dosage Form : Disperse System, Vol ke-3*, 495-498, Marcel Dekker Inc, New York.
- Majeed, A. and Khan, N. A. 2019. 'Ocular in situ gel: An overview', *Journal of Drug Delivery and Therapeutics*, 9(1), pp. 337–347. doi: 10.22270/jddt.v9i1.2231.
- Miljkovic, V. et al. 2014. 'Interactions of metronidazole with other medicines: A brief review', *Pharmazie*, 69(8), pp. 571–577. doi: 10.1691/ph.2014.3951.
- M.A. Fathalla, Z., Vangala, A., Longman, M., Khaled, K.A., Hussein, A.K., El-Garhy, O.H., Alany, R.G., 2017. *Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterisation, toxicity and transcorneal permeation studies*. Eur. J. Pharm. Biopharm. 114, 119–134.
- Nirosha, M. et al. 2017. 'Formulation and Evaluation of Itraconazole Ophthalmic In Situ Gels', *Indo American Journal of Pharmaceutical Sciences*, 4(05), pp. 1101–1108.
- Rarokar, N. R., Saoji, S. D. and Khedekar, P. B. 2018. 'Investigation of effectiveness of some extensively used polymers on thermoreversible properties of Pluronic® tri-block copolymers', *Journal of Drug Delivery Science and Technology*, 44, pp. 220–230. doi: 10.1016/j.jddst.2017.12.002.
- Redigueri, Camila F., Valentina Porta, Diana S.G. Nunes et al. 2011. *Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole*, *Journal of Pharmaceutical Sciences*, 7(5), pp.

1618–1627 doi : 10.1002/jps.22409

- Rowe, R. C., Sheskey, P. J. and Quinn, M. E. 2009. *Handbook of Pharmaceutical Excipients 6th Edition. 6th edn.* UK: Pharmaceutical Press.
- Russo, E. and Villa, C. 2019. Poloxamer hydrogels for biomedical applications. *Pharmaceutics*. 11.(671): 1–17.
- Srigyan, D., Gupta, M. and Behera, H. S. 2017 '*Keratitis: An Inflammation of Cornea*', *Ec Ophthalmology*, 6, pp. 171–177.
- Teweldemedhin, M., Gebreyesus, H., Atsbaha, A.H., Asgedom, S.W., 2017. *Bacterial profile of ocular infections: a systematic review.* *BMC Ophthalmol.* 17, 1–9.